251 CONSUMERS ROAD, TORONTO, A6
Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
News, Letter Re Change in Certifying Accountant
Changes in Board, Management or Compensation
Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Reports Second Quarter 2025 Results
Q2
Q1
Q3
FY 2023 amended
FY 2023
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
PRER14A
PRE 14A
Notification Filed by a National Security Exchange
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
S-1MEF